STT-5058 is an anti-apoC3 human antibody targeting novel and unique epitopes on apoC3 that lower triglycerides and increase clearance of atherogenic remnant lipoproteins. Increased triglycerides and remnant lipoproteins are known factors that lead to cardiovascular disease.
Our lead antibody STT-5058 has recycling properties that are pH-dependent and enable clearing multiple apoC3-containing lipoproteins. This antibody was developed in collaboration with argenx (NASDAQ: ARGX), where Staten benefits from their experience in antibody discovery and development.
More about out lead antibody in our recently published Nature Medicine paper.
ApoC3 is a small apolipoprotein that inhibits the uptake of lipoprotein particles by the liver and inhibits the activity of lipoprotein lipase leading to high levels of lipoproteins and triglycerides. It is secreted from the liver and small intestine and circulates on both triglyceride-rich lipoproteins such as very-low-density-lipoproteins (VLDL), chylomicrons in addition to high-density lipoproteins.
Population groups with loss-of-function mutations in apoC3 have reduced incidence of vascular and heart diseases. High levels of apoC3 correlates with higher amounts of triglycerides and increased incidence of vascular and heart disease. This supports the potential of the anti-apoC3 antibody to act as key molecule in dyslipidemia management.